DOI: http://dx.doi.org/10.22516/25007440.6

Hepatitis alcohólica: revisión con énfasis en trasplante hepático y alternativas de tratamiento médico

David Ríos, Dariana Pereira, Juan Carlos Restrepo

Resumen


La hepatitis alcohólica es un síndrome clínico caracterizado por ictericia, ascitis y eventualmente falla hepáti- ca aguda secundarios al consumo de alcohol; la prevalencia de la enfermedad va en aumento como conse- cuencia del incremento de la exposición a factores de riesgo y la mayoría de los pacientes son asintomáticos hasta que se presenta un importante compromiso de la función hepática, lo que dificulta el diagnóstico tem- prano y se traduce en alta morbimortalidad. El trasplante hepático se postula como una opción de tratamiento válida para pacientes seleccionados, con grandes perspectivas a futuro, sin embargo su realización aún es controvertida; por otro lado, existen opciones de tratamiento médico como los esteroides, la pentoxifilina y la n-acetilcisteína, cuyo impacto en la morbimortalidad es respaldada por la medicina basada en la evidencia. Con esta revisión se pretende abordar los conceptos actuales del tratamiento médico y quirúrgico de la hepatitis alcohólica. 


Palabras clave


Hepatitis alcohólica; trasplante de hígado; tratamiento

Texto completo:

PDF PDF (English)

Referencias


O’Shea R, Dasarathy S, McCullough A. Alcoholic liver disease. Hepatology. 2010;51:307-28.

Burra P, Lucey M. Liver transplantation in alcoholic patients. TransplInt. 2005;18:491-98.

Ceccanti M, Attili A, Balducci G, Attilia F, Giacomelli S, Rotondo C, et al. Acute alcoholic hepatitis. J Clin Gastroenterol. 2006;40:833-84.

Bird G, Williams R. Factors determining cirrhosis in alcoho- lic liver disease. Mol Aspects Med. 1988;10:97-105.

Sorrell M, Mukherjee S. Non-Alcoholic Steatohepatitis (NASH). Curr Treat Options Gastroenterol. 1999;2:447-50.

Suthat L. Clinical Characteristics and Mortality of Hospitalized Alcoholic Hepatitis Patients in the United States. J Clin Gastroenterol. 2011:45.

Naveau S, Giraud V, BorottoE, Aubert A, Capron F, Chaput J. Excess weight risk factor for alcoholic liver disease. Hepatology. 1997;25:108-11.

Becker U, Deis A, Sørensen T, Grønbaek M, Borch-Johnsen K, Müller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23:1025-9.

Lischner M, Alexander J, Galambos J. Natural history ofalcoholic hepatitis. I. The acute disease. Am J Dig Dis. 1971;16:481-94.

Seitz H, Egerer G, Simanowski A, Waldherr R, Eckey R, Agarwal P, et al. Human gastric alcohol dehydrogenase acti- vity: effect of age, sex, and alcoholism. Gut. 1993;34:1433-37.

Mandayam S, Jamal M, Morgan T. Epidemiology of alcoho- lic liver disease. Semin Liver Dis. 2004;24:217-32.

Day P, Bassendine, F. Genetic predisposition to alcoholic liver disease. Gut. 1992;33:1444-47.

Stickel F, Hampe J. Genetic determinants of alcoholic liver disease. Gut. 2011;67:150-59.

Stickel F, Buch S, Lau K, zu Schwabedissen M, Berg T, Ridinger M, et al.Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011;53(1):86-95.

Stinson F, Grant B, Dufour M. The critical dimension of eth- nicity in liver cirrhosis mortality statistics. Alcohol Clin Exp Res. 2001;25:1181-87.

Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002;35:635-38.

Mathurin P, Beuzin F, Louvet A, Carrie-Ganne N, Balian A, Trinchet JC, et al. Fibrosis progressionoccurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther. 2007;25:1047-54.

Mendez-Sanchez N, Meda-Valdes P, Uribe M. Alcoholic liver disease. An update. Ann Hepatol. 2005;4:32-42.

Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med. 1999;48:184-8.

Singal A, Anand B. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol. 2007;41:761-72.

Singal A, Sagi S, Weinman S, Snyder N. Impact of hepatitis C on the outcome and severity of acute alcoholic hepatitis. Eur J Gastroenterol and Hepatol. 2011;23:204-9.

Crews F, BecharaR, Brown L, Guidot D, Mandrecker P, Oak S, et al. Cytokines and alcohol. Alcoholism: Clinical & Experimental Research. 2006;30:720-30.

Lucey M, Mathurin P, & Morgan T. Alcoholic hepatitis. New England Journal of Medicine 2009;360(26):2758-2769.

Rao R, Seth A, ShethP. Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. American Journal of Physiology e Gastrointestinal and Liver Physiology. 2004;286:881-84.

Changqing M, Elizabeth M. Histopathologic Evaluation of Liver Biopsy for Cirrhosis. Adv Anat Pathol. 2012;19:220-30.

Gregory D, Levi D. The clinical-pathologic spectrum of

alcoholic hepatitis. Am J Dig Dis. 1972;17:479-89.

Purohit V, Russo D. Cellular and molecular mechanisms of alcoholic hepatitis: introduction and summary of the symposium. Alcohol. 2002;27:3-6.

Kulkarni K, Tran T, Medrano M, Yoffe B, Goodgame R.

The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. Journal of clinical gastroen- terology. 2004;38:453-59.

Dunn W, Jamil L, Brown L, Wiesner R, Kim W, Menon K, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology. 2005;41:353-58.

Forrest E, Evans C, Stewart S, Phillips M, Oo Y, McAvoy N, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alco- holic hepatitis score. Gut. 2005;54:1174-9.

Conn H. Steroid treatment of alcoholic hepatitis. The yeas and the nays. Gastroenterology. 1978;74:319-22.

Helman R, Temko M, Nye S, Fallon H. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med. 1971;74:311-21.

Porter H, Simon F, Pope C,Volwiler W, Fenster F.Corticosteroid Therapy in Severe Alcoholic Hepatitis - A Double-Blind Drug Trial. N Engl J Med. 1971;284:1350-5.

Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confoun- ding variables. Gut. 1995;37:113-8.

Rambaldi A, Saconato H, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticos- teroids for alcoholic hepatitis–a CochraneHepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008;27:1167-78.

Mathurin P, O’Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta- analysis of individual patient data. Gut. 2011;60:255-60.

Kim D, Suk K, Park S, Tak W, Yim H, Um S, et al. Short-term survival in patients with severe alcoholic hepatitis treated with pentoxifylline vs. corticosteroid: a non-inferiority trial. Journal of Hepatology. 2013;58,219-20.

Singh S, Goyal O, Singla P, Gupta D, Sood A, Singh R, et al. Corticosteroid Plus Pentoxifylline Is Not Better than Corticosteroid Alone for Improving Survival in Severe Alcoholic Hepatitis (COPE Trial). Dig Dis Sci. 2012;57:1664-71.

McHutchison J, Runyon B, Draguesku J, et al. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology. 1991;14:96.

Whitfield K, et al. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 4 2009.

Garcõa J, Hernandez G, Lopez A, et al. Pentoxifilina ver- sus esteroide en la sobrevivencia a corto plazo en hepati- tis aguda alcohólica severa. Medicina Interna de México. 2012;28:228.

O’Shea R, Dasarathy S, McCullough A. Alcoholic liver disease. Hepatology. 2010;51:307-28.

Parker R, et al. Systematic review: pentoxifylline for the treatment of

severe alcoholic hepatitis. Alimentary pharma- cology & therapeutics. 2013.

De B, Gangopadhyay S, Dutta D, et al. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15:1613.

Mathurin P, Louvet A, Duhamel A, et al. Prednisolone With vs Without Pentoxifylline and Survival of Patients With Severe Alcoholic Hepatitis: A Randomized Clinical Trial. JAMA. 2013;310(10):1033-41.

Sidhu S, Goyal O, Singla P, et al. Corticosteroid plus pen- toxifylline is not better than corticosteroid alone for impro- ving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci. 2012;57:1664-71.

Mathurin P. Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6-month survival: results of the Corpentox trial. Hepatology. 2011;54(1):81.

Louvet A, Dao T, Nahon P, et al. Pentoxifylline does not improve shortterm survival in severe alcoholic hepatitis in combination with corticosteroids: results of a randomized controlled trial. J Hepatol. 2012;56:533.

Anderson H, Baumburg B. Alcohol in Europe. A public health perspective. London: Institute of Alcohol Studies; 2006.

Zatonski W, Sulkowska U, Manczuk M, Rehm J, Boffetta P,

Lowenfels A, et al. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe.Eur Addict Res. 2010;16:193-201.

Paredes S, Kozicki P, Kukuda H, Rossetti M, Batlle A. S-Adenosyl-Lmethionine: its effect on aminolevulinate- dehydratase and glutathione in acute ethanol intoxication. Alcohol. 1987;4:81-85.

Fernandez-Checa J, Ookhtens M, Kaplowitz N. Effect of chronic ethanol feeding on rat hepatocytic glutathione. Compartmentation, efflux, and response to incubation with ethanol. J Clin Invest. 1987;80:57-62.

Fernandez-Checa J, Ookhtens M, Kaplowitz N. Effect of chronic ethanol feeding on rat hepatocytic glutathione. Relationship of cytosolic glutathione to efflux and mito- chondrial sequestration. J Clin Invest. 1989;83:1247-52.

Phillips M, et al. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis -a randomised clini- cal trial. Journal of hepatology. 2006;44:784-90.

Stewart S, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. Journal of hepatology. 2007;47:277-83.

Moreno C, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: A randomized multicenter controlled trial. Journal of hepatology. 2010;53:1117-22.

Nguyen-Khac E, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. New England Journal of Medicine. 2011;365:1781-9.

European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57(2):399-420.

Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani G, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant. 2010;10(1):138-48.

Annual Report - OPTN [Internet]. [citado 11 de noviembre de 2015]. Recuperado a partir de: http://optn.transplant. hrsa.gov/converge/data/annualReport.asp

Biselli M, Gramenzi A, Del Gaudio M, et al. Long term follow-up and outcome of liver transplantation for alcoho- lic liver disease: a single center case–control study. J Clin Gastroenterol. 2010;44:52-57.

Pfitzmann R, Schwenzer J, Rayes N, et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2007;13:197-205.

Bjornsson E, Olsson J, Rydell A, et al. Long-term follow-up of patients withalcoholic liver disease after liver transplanta- tion in Sweden: impact of structured management on recidi- vism. Scand J Gastroenterol. 2005;40:206-16.

Dureja P, Lucey M. The place of liver transplantation in the treatment of severe alcoholic hepatitis. J Hepatol. 2010;52:759-64.

Ceccanti M, Attili A, Balducci G, et al. Acute alcoholic hepa- titis. J ClinGastroenterol. 2006;40:833-41.

Louvet A, Diaz E, Dharancy S, et al. Early switch to pen- toxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol. 2008;48:465-70.

Louvet A, Naveau S, Abelnour M, et al. The Lille model: a new tool fortherapeutic strategy in patients with severe alcoholic hepatitis treated withsteroids. Hepatology. 2007;45:1348-54.

Mathurin P, O’Grady J, Carithers RL, et al. Corticosteroids improve short termsurvival in patients with severe alcoho- lic hepatitis: meta-analysis ofindividual patient data. Gut. 2011;60:255-60.

Singal A, Bashar H, Anand B, et al. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoho- lic cirrhosis: exploratory analysis from the UNOS database. Hepatology. 2012; 55:1398.

Mathurin P, Moreno C, Samuel D, et al. Early liver trans- plantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790.

Beresford T, Everson G. Liver transplantation for alcoholic liver disease: bias, beliefs, 6 month rule and relapse - but where are the data. Liver Transpl. 2002;6:777-8.

Tandon P, Goodman K, Ma M, et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol. 2009;104:1700-6.

Lucey M, Brown K, Everson G, Fung J, Gish R, Keeffe E, et al. Minimal criteria for placement of adults on the liver trans- plant waiting list: a report of a national conference organi- zed by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver TransplSurg. 1997;3:628-37.

DiMartini A, Day N, Dew M, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl. 2006;12:813-20.

Kelly M, Chick J, Gribble R, et al. Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol. 2006;41:278-83.

Consensus conference: indications for liver transplantation, January 19 and 20, 2005 Lyon-Palais de Congres: text of recommendations. Liver Transplant. 2006;12:998-1011.

Neuberger J, Adams D, MacMaster P, Maidment A, Speed M. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. BMJ. 1998;317:172-5.

McCallum S, Masterton G. Liver transplantation for alcoho- lic liver disease: a systematic review of psychosocial selec- tion criteria. Alcohol. 2006;41:358-63.

Wells J, Adnan S, Rashmi A, Tome S, Hughes S, Dureja P et al. The impact of acute alcoholic hepatitis in the explanted recipient liver on outcome after liver transplantation. Liver Transplantation. 2007;13:1728-35.

Chambless DL, Baker MJ, Baucom DH, et al: Update on empirically alidated therapies, II. TheClinical Psychologist. 1998;51:3-16.

Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised contro- lled trial. Lancet. 2003;361:1677-85.

Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O’Malley SS, Swift RM, Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298:1641-51.

Medication treatment of different types of alcoholism. Am J Psychiatry. 2010;167(6):630-9.

Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D’Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind con- trolled study. Lancet. 2007;370:1915-22.

Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL. Nutritional therapy in cirrhosis or alcoholic hepa- titis: a systematic review and meta-analysis. Liver Int. 2015;35(9):2072-8.

Marchesini G, Bianchi G, Rosi B, Brizi M, Melchionda N. Nutritional treatment with branched chain aminoacids in dvanced liver cirrhosis. J Gastroenterol. 2000;35:7-12.


Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2016 Revista Colombiana de Gastroenterología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN versión impresa 0120-9957

ISSN versión en línea 2500-7440

  Licencia de Creative Commons
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.